Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ALPRAZOLAM Cause Intentional product use issue? 320 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 320 reports of Intentional product use issue have been filed in association with ALPRAZOLAM (Alprazolam). This represents 0.7% of all adverse event reports for ALPRAZOLAM.

320
Reports of Intentional product use issue with ALPRAZOLAM
0.7%
of all ALPRAZOLAM reports
79
Deaths
118
Hospitalizations

How Dangerous Is Intentional product use issue From ALPRAZOLAM?

Of the 320 reports, 79 (24.7%) resulted in death, 118 (36.9%) required hospitalization, and 5 (1.6%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ALPRAZOLAM. However, 320 reports have been filed with the FAERS database.

What Other Side Effects Does ALPRAZOLAM Cause?

Drug abuse (8,827) Toxicity to various agents (7,157) Completed suicide (4,873) Drug ineffective (4,040) Overdose (2,967) Drug dependence (2,743) Somnolence (2,461) Intentional overdose (2,389) Death (2,317) Suicide attempt (2,313)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which ALPRAZOLAM Alternatives Have Lower Intentional product use issue Risk?

ALPRAZOLAM vs ALPROSTADIL ALPRAZOLAM vs ALTEPLASE ALPRAZOLAM vs ALTERNARIA ALTERNATA ALPRAZOLAM vs ALTHIAZIDE ALPRAZOLAM vs ALTHIAZIDE\SPIRONOLACTONE

Related Pages

ALPRAZOLAM Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue ALPRAZOLAM Demographics